Cargando…

Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study

Hepatocellular carcinoma (HCC) patients experience high rates of recurrence following hepatectomy. Many herbal preparations used in traditional Chinese medicine have been shown to improve the postoperative condition of cancer patients. This retrospective study examined the efficacy and safety of Jia...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Rui, Fang, Chongkai, Chen, Chuyao, Zhang, Ying, Yao, Ruiwei, Wang, Jinan, Shi, Hanqian, Feng, Kunliang, Hu, Mingli, Zhong, Chong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561391/
https://www.ncbi.nlm.nih.gov/pubmed/37818186
http://dx.doi.org/10.3389/fphar.2023.1212116
_version_ 1785117911866671104
author Luo, Rui
Fang, Chongkai
Chen, Chuyao
Zhang, Ying
Yao, Ruiwei
Wang, Jinan
Shi, Hanqian
Feng, Kunliang
Hu, Mingli
Zhong, Chong
author_facet Luo, Rui
Fang, Chongkai
Chen, Chuyao
Zhang, Ying
Yao, Ruiwei
Wang, Jinan
Shi, Hanqian
Feng, Kunliang
Hu, Mingli
Zhong, Chong
author_sort Luo, Rui
collection PubMed
description Hepatocellular carcinoma (HCC) patients experience high rates of recurrence following hepatectomy. Many herbal preparations used in traditional Chinese medicine have been shown to improve the postoperative condition of cancer patients. This retrospective study examined the efficacy and safety of Jianpi Huayu decoction (JPHYD) as adjuvant therapy for HCC following hepatectomy. HCC patients received postoperative management according to Chinese Society of Clinical Oncology recommendations, either alone (Control group) or in addition to daily JPHYD (1 week in hospital and 3 months after release). To reduce selection bias, we performed 1:1 propensity score matching between the Control and JPHYD groups. The main endpoint was recurrence-free survival (RFS), and secondary endpoints included overall survival (OS) and adverse event frequency. A total of 207 patients meeting inclusion criteria were enrolled, 127 in the Control group and 80 in the JPHYD group. Patients were then propensity score-matched, yielding each group of 80. Recurrence-free survival rate was significantly higher in the JPHYD group than in the Control group at 1 year (67.9% vs. 38.1%), 2 years (39.1% vs. 26.2%), and 3 years (31.3% vs. 26.2%) following hepatectomy (HR 0.5666 [95%CI, 0.3655 to 0.8784]; p = 0.0066). Additionally, OS was significantly higher in the JPHYD group than the Control group at 1 year (94.3% vs. 81.9%), 2 years (76.4% vs. 58.8%), and 3 years (66.3% vs. 51.4%) following hepatectomy (HR 0.5199 [95%CI, 0.2849 to 0.9490]; p = 0.027). Adverse events frequencies did not differ between the two groups. In conclusion, JPHYD can safely improve RFS and OS following hepatectomy for HCC.
format Online
Article
Text
id pubmed-10561391
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105613912023-10-10 Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study Luo, Rui Fang, Chongkai Chen, Chuyao Zhang, Ying Yao, Ruiwei Wang, Jinan Shi, Hanqian Feng, Kunliang Hu, Mingli Zhong, Chong Front Pharmacol Pharmacology Hepatocellular carcinoma (HCC) patients experience high rates of recurrence following hepatectomy. Many herbal preparations used in traditional Chinese medicine have been shown to improve the postoperative condition of cancer patients. This retrospective study examined the efficacy and safety of Jianpi Huayu decoction (JPHYD) as adjuvant therapy for HCC following hepatectomy. HCC patients received postoperative management according to Chinese Society of Clinical Oncology recommendations, either alone (Control group) or in addition to daily JPHYD (1 week in hospital and 3 months after release). To reduce selection bias, we performed 1:1 propensity score matching between the Control and JPHYD groups. The main endpoint was recurrence-free survival (RFS), and secondary endpoints included overall survival (OS) and adverse event frequency. A total of 207 patients meeting inclusion criteria were enrolled, 127 in the Control group and 80 in the JPHYD group. Patients were then propensity score-matched, yielding each group of 80. Recurrence-free survival rate was significantly higher in the JPHYD group than in the Control group at 1 year (67.9% vs. 38.1%), 2 years (39.1% vs. 26.2%), and 3 years (31.3% vs. 26.2%) following hepatectomy (HR 0.5666 [95%CI, 0.3655 to 0.8784]; p = 0.0066). Additionally, OS was significantly higher in the JPHYD group than the Control group at 1 year (94.3% vs. 81.9%), 2 years (76.4% vs. 58.8%), and 3 years (66.3% vs. 51.4%) following hepatectomy (HR 0.5199 [95%CI, 0.2849 to 0.9490]; p = 0.027). Adverse events frequencies did not differ between the two groups. In conclusion, JPHYD can safely improve RFS and OS following hepatectomy for HCC. Frontiers Media S.A. 2023-09-25 /pmc/articles/PMC10561391/ /pubmed/37818186 http://dx.doi.org/10.3389/fphar.2023.1212116 Text en Copyright © 2023 Luo, Fang, Chen, Zhang, Yao, Wang, Shi, Feng, Hu and Zhong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Luo, Rui
Fang, Chongkai
Chen, Chuyao
Zhang, Ying
Yao, Ruiwei
Wang, Jinan
Shi, Hanqian
Feng, Kunliang
Hu, Mingli
Zhong, Chong
Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study
title Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study
title_full Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study
title_fullStr Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study
title_full_unstemmed Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study
title_short Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study
title_sort adjuvant therapy with jianpi huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561391/
https://www.ncbi.nlm.nih.gov/pubmed/37818186
http://dx.doi.org/10.3389/fphar.2023.1212116
work_keys_str_mv AT luorui adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy
AT fangchongkai adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy
AT chenchuyao adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy
AT zhangying adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy
AT yaoruiwei adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy
AT wangjinan adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy
AT shihanqian adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy
AT fengkunliang adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy
AT humingli adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy
AT zhongchong adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy